Camaisa Allan bought CLDI
December 21, 2023 · Form 4 insider transaction
Camaisa Allan bought 100,000 shares of Calidi Biotherapeutics, Inc., a transaction worth N/A. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 14 days after the transaction.
Footnotes
Pursuant to the Issuer's 2023 Equity Incentive Plan (the "2023 Plan"), on December 21, 2023 (the "Grant Date"), the Reporting Person was granted 100,000 Non-Qualified Stock Options (the "Options") at an exercise price of $1.80, which is equal to the closing price of the Issuer's common stock on December 21, 2023 in consideration of Mr. Camaisa personally guaranteeing the raising of $12,500,000 of Series B preferred stock of Calidi Biotherapeutics, a Nevada corporation ("Old Calidi"), in connection with the Agreement and Plan of Merger, as amended ("Merger Agreement"), by and among First Light Acquisition Group, Inc., FLAG Merger Sub, Inc. ("Merger Sub"), First Light Acquisition Group, LLC, Allan Camaisa and Old Calidi. On September 12, 2023, Merger Sub merged with and into Old Calidi, with Old Calidi surviving the merger. The options were granted in a transaction exempt under Rule 16b-3.